Skip to site content

Patients & Visitors

Menu
Patients & Visitors Menu

Monoclonal Antibody Treatment

**NOTE**

Jackson Purchase Medical Center is aware that the Food and Drug Administration (FDA) has halted the use of two COVID-19 monoclonal antibody therapies because newly released data indicates that they are not effective against the Omicron variant. These include Lilly’s bamlanivimab plus etesevimab and Regeneron’s casirivimab plus imdevimab. We previously offered casirivimab plus imdevimab at our hospital but are no longer providing this treatment given that it is no longer authorized for use at this time.

  • What is bamlanivimab and etesevimab/casirivimab and imdevimab monoclonal antibody treatment?

    Bamlanivimab and etesevimab/Casirivimab and imdevimab are monoclonal antibody therapies that help treat non-hospitalized patients with a mild or moderate case of COVID-19 (SARS-CoV-2). Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful viruses. These therapies are designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.

    Bamlanivimab and etesevimab/Casirivimab and imdevimab have received emergency use authorization (EUA) from the Food and Drug Administration (FDA).

  • Who is a candidate for monoclonal antibody treatment?

    Adults and adolescents 12 years of age or older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.

    Patients must meet specific clinical criteria including:

    • Lab-confirmed COVID-19 positive test
    • Stable enough to not require hospitalization
    • Be within 10 days of symptom onset
    • [FOR casirivimab and imdevimab]: Been exposed to a COVID-19-positive patient and meets the risk profile for benefiting from the therapy

    In addition to meeting the above criteria, patients must also have an order from a provider to receive this treatment.

  • Who is not a candidate for this treatment?

    This treatment will not be considered for patients who are currently hospitalized due to COVID-19, require oxygen therapy for COVID-19, and/or have a known hypersensitivity to bamlanivimab and etesevimab/ casirivimab and imdevimab.

  • How do I qualify for this treatment?

    This therapy requires an order from a healthcare provider.

    You may:

    1. Contact your primary care physician (PCP) to make an appointment, OR
    2. Call our Provider Referral Line at 855.769.DOCS or visit our Find a Provider feature here.
  • What should I expect?

    Your physician’s office will provide steps on how and where you will be receiving your treatment. Treatment is administered either by intravenous route (using IV therapy) or by subcutaneous injections. Patients receiving treatment at Jackson Purchase Medical Center will be required to stay for a duration of up to 2 hours.

Important facts about bamlanivimab and etesevimab

For information on the authorized use of bamlanivimab and etesevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English) 
Fact Sheet for Patients, Parents and Caregivers (Spanish)

Important facts about casirivimab and imdevimab

For information on the authorized use of casirivimab and imdevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English) 
Fact Sheet for Patients Parents and Caregivers (Spanish) 

Helpful Links

Team Kentucky Monoclonal Antibody